Navigation Links
Cancer drugs may help stop major parasite
Date:7/16/2010

A parasite estimated to afflict as many as 12 million people worldwide relies on a family of genes that should make it vulnerable to compounds developed to treat cancer and other disorders, researchers at Washington University School of Medicine in St. Louis have found.

Scientists searched the genome of the parasite Leishmania to determine that it has three kinds of TOR kinases, proteins that are linked to cell growth and cancer and have been longstanding targets for drug development. When they removed the proteins individually, they found that all three were critical either to the parasite's ability to survive or its ability to cause infections.

"If we can hit any of these proteins with a drug that will inhibit them, we should be able to strike a significant blow against Leishmania," says senior author Stephen Beverley, PhD, the Marvin A. Brennecke Professor and head of Molecular Microbiology. "Given the numerous inhibitors already available, I think there's a pretty good chance that we'll be able to identify a compound that specifically inhibits one of Leishmania's TOR kinases."

The finding appears online in The Proceedings of the National Academy of Sciences.

Infection with the Leishmania parasite, or leishmaniasis, is mainly spread by sand fly bites and is a major public health problem in Asia, Africa, the Middle East and other parts of the developing world. Symptoms include large skin lesions, fever, swelling of the spleen and liver, and, in more serious forms of the disease, disfigurement. The most severe form of leishmaniasis, a condition sometimes called black fever, is fatal if left untreated and is estimated to kill more humans than any other parasite except Plasmodium falciparum, the malaria parasite.

Mammals have only one TOR kinase protein, and drug developers have targeted it to block immune system rejection of transplanted organs, to treat certain forms of cancer an
'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert  

Page: 1 2

Related biology news :

1. WSU researchers find way to make cancer cells more mortal
2. New arsenic nanoparticle blocks aggressive breast cancer
3. Mechanism for link between high fat diet and risk of prostate cancer and disorders unveiled
4. Divide and conquer: Genes decide who wins in the bodys battle against cancer
5. Mahjong gene is key player when cancer, normal cells compete
6. CWRU dental researchers discover human beta defensins-3 ignite in oral cancer growth
7. The Samuel Waxman Cancer Research Foundation awards $1.54 million in research grants for 2010-2011
8. A*STAR scientists score hat-trick against cancer
9. Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy
10. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists
11. DNA discovery opens new door to develop tools, therapies for hereditary cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer drugs may help stop major parasite
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season ... as Acuity Market Intelligence reports that the long anticipated ... forecasts that intensifying demand for smart phones, tablets, and ... global market of 2.5 billion users with nearly 4.8 ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... N.Y. With support from the Photosynthetic Systems Division ... the School of Science at Rensselaer Polytechnic Institute are ... workings of the photosynthetic protein, Photosystem II. The high-impact ... photosynthesis for artificial use as an abundant source of ...
... Dec. 3, 2013 (Toronto) - People who carry a high-risk ... in childhood, decades before the illness appears, new research from ... The gene, called SORL1, is one of a number of ... the most common form of the illness. SORL1 carries the ...
... This news release is available in ... growing number of industries, workers are often unknowingly exposed to nanoparticles ... on health? Professor Denis Girard from the INRSInstitut Armand-Frappier Research Centre ... wide variety of NPs with a view to setting the record ...
Cached Biology News:Rensselaer researchers to map step-by-step mechanism of photosynthesis 2Rensselaer researchers to map step-by-step mechanism of photosynthesis 3Rensselaer researchers to map step-by-step mechanism of photosynthesis 4Alzheimer's risk gene may begin to affect brains as early as childhood, CAMH research shows 2Alzheimer's risk gene may begin to affect brains as early as childhood, CAMH research shows 3Thousands of new particles in workplaces despite large knowledge gap 2
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... ... savvy suggestions for effective interactive healthcare marketing at Digital Pharma West. , ... (PRWEB) -- Viscira™, a leading ... relevant presentation entitled, “Maximizing Return on Interactive” at the Digital Pharma West (DPW) conference ...
... , July 7 Cardium Therapeutics (NYSE Amex: CXM ) today reported ... it has now resolved matters relating to the Company,s exchange listing compliance. , ... (Logo:   http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO ) , , ... , , , ...
... ... in their own lab with new Kinase Enzyme Systems from Promega and SignalChem. ... Madison, WI (PRWEB) ... flexible and complete kinase solution for the profiling of lead compounds against kinases representative ...
Cached Biology Technology:Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference 2Cardium Regains Listing Compliance With NYSE Amex 2Cardium Regains Listing Compliance With NYSE Amex 3Cardium Regains Listing Compliance With NYSE Amex 4Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome 2
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
...
Biology Products: